The MHRA has approved Sentynl’s (wholly-owned by Zydus Lifesciences) Nulibry (fosdenopterin) injection as a treatment of molybdenum cofactor deficiency (MoCD) Type A in Great Britain
The approval was based on 3 clinical evaluations depicting a 5.5 times decreased death risk and 85.5% survival probability at 3yrs. in Nulibry-treated vs untreated MoCD Type A patients
Acquired from BridgeBio in Mar 2022, Nulibry is a FIC synthetic cPMP substrate replacement therapy that received the US FDA’s approval in 2021 for the same indication
Ref: Sentynl Therapeutics | Image: Sentynl Therapeutics
Related News:- BridgeBio Pharma and Sentynl Therapeutics Receive EC’s Conditional Marketing Authorization for Nulibry (fosdenopterin) to Treat MoCD Type A
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
